PRGON Stock Chart & Stats
$249.00
-$400.24(-69.37%)
At close: 4:00 PM EDT
$249.00
-$400.24(-69.37%)
Day’s Range― - ―
52-Week Range$249.00 - $557.52
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$35.02B
Enterprise Value$4.45K
Total Cash (Recent Filing)$399.70M
Total Debt (Recent Filing)$3.29B
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 11, 2026EPS Estimate
8.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,769,240
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$288.59Price Target Upside15.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)37.48
Revenue Forecast (FY)$69.07B
Bulls Say, Bears Say
Bulls Say
Market Share And Service-level GainsShare gains while the underlying categories declined indicate Perrigo is strengthening retailer relevance and competitive execution. Higher service levels should support customer relationships, distribution reliability, and repeat business across its private-label and branded self-care portfolio over the next several quarters.
Infant Formula TurnaroundThe Infant Formula recovery provides a meaningful earnings growth engine within the portfolio. Capacity rationalization, efficiency improvements, and lower scrap or obsolescence indicate that the improvement is operationally grounded and could continue supporting mix and profitability.
Cash Generation And Debt ReductionPositive free cash flow gives Perrigo internal funding capacity despite accounting losses, while divestiture proceeds have been directed toward debt reduction. If sustained, this combination can lower interest burden, improve liquidity resilience, and increase flexibility for operational investment.
Bears Say
Shrinking Revenue And Heavy LossesPersistent sales deterioration reduces operating leverage and makes it harder to absorb fixed manufacturing and corporate costs. The shift to substantial operating and net losses weakens earnings quality, limits reinvestment capacity, and raises execution risk until revenue and profitability stabilize.
Elevated LeverageDebt remains high relative to equity even after recent repayments, leaving Perrigo exposed to interest costs and reducing financial flexibility. Elevated leverage can constrain acquisitions, innovation spending, and shareholder returns while the company works to restore sustainable profitability.
CEO Transition And Governance OverhangA CEO departure linked to a conduct violation can disrupt strategic continuity and weaken confidence in leadership oversight during an operational turnaround. Although new independent directors strengthen the board, successor selection and execution discipline remain important medium-term risks.
Perrigo Company News
PRGON FAQ
What was Perrigo Company plc’s price range in the past 12 months?
Perrigo Company plc lowest stock price was $249.00 and its highest was $557.52 in the past 12 months.
What is Perrigo Company plc’s market cap?
Perrigo Company plc’s market cap is $35.02B.
When is Perrigo Company plc’s upcoming earnings report date?
Perrigo Company plc’s upcoming earnings report date is Nov 11, 2026 which is in 63 days.
How were Perrigo Company plc’s earnings last quarter?
Perrigo Company plc released its earnings results on Aug 05, 2026. The company reported $8.57 earnings per share for the quarter, beating the consensus estimate of $6.65 by $1.92.
Is Perrigo Company plc overvalued?
According to Wall Street analysts Perrigo Company plc’s price is currently Undervalued.
Does Perrigo Company plc pay dividends?
Perrigo Company plc does not currently pay dividends.
What is Perrigo Company plc’s EPS estimate?
Perrigo Company plc’s EPS estimate is 8.86.
How many shares outstanding does Perrigo Company plc have?
Perrigo Company plc has 138,769,240 shares outstanding.
What happened to Perrigo Company plc’s price movement after its last earnings report?
Perrigo Company plc reported an EPS of $8.57 in its last earnings report, beating expectations of $6.65. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perrigo Company plc?
Currently, no hedge funds are holding shares in MX:PRGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$288.59 (15.90% Upside)
$288.59 (15.90% Upside)
Blogger Sentiment
Bullish
MX:PRGON Sentiment 80%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.55%
12-Months-Change
Fundamentals
Return on Equity
17.94%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
PRGON Company Deck
PRGON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all MX:PRGON earnings summariesPRGON Stock 12 Month Forecast
Average Price Target
$288.59
▲(15.90% Upside)